Anzeige
Mehr »
Mittwoch, 29.04.2026 - Börsentäglich über 12.000 News
250 Tage bis zum Pentagon-Magnetverbot: Wie ein 46-Mio.-CAD-Small-Cap profitieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA9E | ISIN: CA14161Y2006 | Ticker-Symbol: CT9
Tradegate
29.04.26 | 19:08
1,102 Euro
-6,29 % -0,074
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARDIOL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARDIOL THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0981,14021:28
1,1041,13221:16

Aktuelle News zur CARDIOL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCardiol Therapeutics Inc: Cardiol to add seven clinical centres to Maveric trial19
DiStocks in Play: Cardiol Therapeutics Inc.19
DiCardiol Therapeutics erweitert Phase-III-Studie auf 25 Standorte36
DiCardiol Therapeutics expands Phase III trial to 25 sites11
DiCardiol Therapeutics Inc.: Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program606Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia...
► Artikel lesen
DiCardiol Therapeutics Inc. - 6-K, Report of foreign issuer4
19.04.Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley - Cardiol Therapeutics90
CARDIOL THERAPEUTICS Aktie jetzt für 0€ handeln
17.04.Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY520Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 17.04.2026 / 15:31 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The...
► Artikel lesen
14.04.Stocks in Play: Cardiol Therapeutics Inc.79
14.04.Cardiol Therapeutics CEO to discuss drug trials in interview19
14.04.CEO von Cardiol Therapeutics erörtert klinische Studien in Live-Interview55
14.04.Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart406Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the...
► Artikel lesen
10.04.Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer42
01.04.Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2025 Update on Operations584Initiated pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER...
► Artikel lesen
01.04.Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer42
25.02.Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer46
25.02.Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference773Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing...
► Artikel lesen
10.02.Cardiol Therapeutics Inc: Cardiol sees phase 2 Archer study results published112
10.02.Stocks in Play: Cardiol Therapeutics Inc.63
10.02.Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer24
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,15